150 related articles for article (PubMed ID: 35971951)
1. Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses.
Han K; Theodore D; McMullen G; Swayze E; McCaleb M; Billioud G; Wieland S; Hood S; Paff M; Bennett CF; Kwoh TJ
Clin Pharmacol Drug Dev; 2022 Oct; 11(10):1191-1202. PubMed ID: 35971951
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Yuen MF; Heo J; Jang JW; Yoon JH; Kweon YO; Park SJ; Tami Y; You S; Yates P; Tao Y; Cremer J; Campbell F; Elston R; Theodore D; Paff M; Bennett CF; Kwoh TJ
Nat Med; 2021 Oct; 27(10):1725-1734. PubMed ID: 34642494
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.
Yuen MF; Lim SG; Plesniak R; Tsuji K; Janssen HLA; Pojoga C; Gadano A; Popescu CP; Stepanova T; Asselah T; Diaconescu G; Yim HJ; Heo J; Janczewska E; Wong A; Idriz N; Imamura M; Rizzardini G; Takaguchi K; Andreone P; Arbune M; Hou J; Park SJ; Vata A; Cremer J; Elston R; Lukić T; Quinn G; Maynard L; Kendrick S; Plein H; Campbell F; Paff M; Theodore D;
N Engl J Med; 2022 Nov; 387(21):1957-1968. PubMed ID: 36346079
[TBL] [Abstract][Full Text] [Related]
4. B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection.
Cremer J; Elston R; Campbell FM; Kendrick S; Paff M; Quinn G; Theodore D
Adv Ther; 2023 Sep; 40(9):4101-4110. PubMed ID: 37393402
[TBL] [Abstract][Full Text] [Related]
5. Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress.
Mak LY; Hui RW; Fung J; Seto WK; Yuen MF
Expert Opin Investig Drugs; 2023; 32(11):971-983. PubMed ID: 37902953
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.
Han K; Cremer J; Elston R; Oliver S; Baptiste-Brown S; Chen S; Gardiner D; Davies M; Saunders J; Hamatake R; Losos J; Leivers M; Hood S; van der Berg F; Paff M; Ritter JM; Theodore D
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):790-801. PubMed ID: 30861337
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies.
Youssef AS; Ismail M; Han K; Magee M; Nader A
Infect Dis Ther; 2024 Jul; 13(7):1515-1530. PubMed ID: 38796564
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications.
Zhou XJ; Lim SG; Lloyd DM; Chao GC; Brown NA; Lai CL
Antimicrob Agents Chemother; 2006 Mar; 50(3):874-9. PubMed ID: 16495245
[TBL] [Abstract][Full Text] [Related]
10. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L
Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364
[TBL] [Abstract][Full Text] [Related]
11. EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B.
Feld JJ; Lawitz E; Nguyen T; Lalezari J; Hassanein T; Martin P; Han SH; Dieterich D; Giard JM; De La Rosa G; Ahmad A; Luo E; Conery AL; Adda N
Antivir Ther; 2022 Dec; 27(6):13596535221127848. PubMed ID: 36382358
[TBL] [Abstract][Full Text] [Related]
12. Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B.
Gane E; Yuen MF; Kim DJ; Chan HL; Surujbally B; Pavlovic V; Das S; Triyatni M; Kazma R; Grippo JF; Buatois S; Lemenuel-Diot A; Krippendorff BF; Mueller H; Zhang Y; Kim HJ; Leerapun A; Lim TH; Lim YS; Tanwandee T; Kim W; Cheng W; Hu TH; Wat C
Hepatology; 2021 Oct; 74(4):1795-1808. PubMed ID: 34037271
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection.
Gupta SV; Fanget MC; MacLauchlin C; Clausen VA; Li J; Cloutier D; Shen L; Robbie GJ; Mogalian E
Drugs R D; 2021 Dec; 21(4):455-465. PubMed ID: 34741731
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
Vandenbossche J; Jessner W; van den Boer M; Biewenga J; Berke JM; Talloen W; De Zwart L; Snoeys J; Yogaratnam J
Adv Ther; 2019 Sep; 36(9):2450-2462. PubMed ID: 31267367
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of setrobuvir, an orally administered hepatitis C virus non-nucleoside analogue inhibitor.
Mallalieu NL; Rahimy MH; Crowley CA; Appleman JR; Smith PF; Freddo JL
Clin Ther; 2014 Dec; 36(12):2047-2063.e3. PubMed ID: 25456558
[TBL] [Abstract][Full Text] [Related]
16. A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants.
Feng S; Gane E; Schwabe C; Zhu M; Triyatni M; Zhou J; Bo Q; Jin Y
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839221
[TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.
Schluep T; Lickliter J; Hamilton J; Lewis DL; Lai CL; Lau JY; Locarnini SA; Gish RG; Given BD
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):350-362. PubMed ID: 27739230
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region.
Han K; Ito H; Elston R; Cremer J; Hood S; Paff M; Theodore D
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0090022. PubMed ID: 36507675
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation.
Beigel JH; Voell J; Muñoz P; Kumar P; Brooks KM; Zhang J; Iversen P; Heald A; Wong M; Davey RT
Br J Clin Pharmacol; 2018 Jan; 84(1):25-34. PubMed ID: 28929521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
